EQS-Adhoc: RHÖN-KLINIKUM Aktiengesellschaft: EBITDA for 2022 above the forecast range on the basis of preliminary figures
|
EQS-Ad-hoc: RHÖN-KLINIKUM Aktiengesellschaft / Key word(s): Preliminary Results
RHÖN-KLINIKUM Aktiengesellschaft: EBITDA for 2022 above the forecast range on the basis of preliminary figures
30-Jan-2023 / 14:01 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
In the course of preparing the consolidated financial statements for the past financial year, the Management Board of RHÖN-KLINIKUM Aktiengesellschaft now assumes that the Group's earnings before interest, taxes, depreciation and amortisation (EBITDA) will be above the forecast published by the company in March 2022 (EBITDA value between EUR 92 million and EUR 102 million). Based on preliminary and unaudited figures, the Management Board currently estimates that the Group's EBITDA will be in a range between EUR 103 million and EUR 109 million.
The Annual Report 2022 and further information on the past financial year will be published on 30 March 2023.
Contact:
Julian Schmitt
Head of Investor Relations & Treasury
+49 9771 65 12250
30-Jan-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
|
| Language: |
English |
| Company: |
RHÖN-KLINIKUM Aktiengesellschaft |
|
Salzburger Leite 1 |
|
97616 Bad Neustadt a.d.Saale |
|
Germany |
| Phone: |
+49 (0)9771 - 65-0 |
| Fax: |
+49 (0)9771 - 97 467 |
| E-mail: |
[email protected] |
| Internet: |
www.rhoen-klinikum-ag.com |
| ISIN: |
DE0007042301 |
| WKN: |
704230 |
| Listed: |
Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Stuttgart, Tradegate Exchange |
| EQS News ID: |
1546697 |
| |
| End of Announcement |
EQS News Service |
1546697 30-Jan-2023 CET/CEST
|
Die wichtigsten Finanzdaten auf einen Blick
|
| |
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
| Umsatzerlöse1 |
1.211,08 |
1.232,91 |
1.303,90 |
1.360,16 |
1.402,01 |
1.446,09 |
1.463,98 |
| EBITDA1,2 |
97,82 |
125,54 |
125,33 |
80,23 |
101,16 |
105,65 |
105,88 |
| EBITDA-Marge3 |
8,08 |
10,18 |
9,61 |
5,90 |
7,22 |
7,31 |
|
| EBIT1,4 |
38,70 |
64,94 |
56,80 |
10,60 |
30,52 |
36,11 |
40,40 |
| EBIT-Marge5 |
3,20 |
5,27 |
4,36 |
0,78 |
2,18 |
2,50 |
2,76 |
| Jahresüberschuss1 |
36,74 |
51,19 |
44,48 |
2,46 |
30,23 |
26,94 |
40,17 |
| Netto-Marge6 |
3,03 |
4,15 |
3,41 |
0,18 |
2,16 |
1,86 |
2,74 |
| Cashflow1,7 |
80,30 |
49,50 |
47,30 |
113,30 |
97,50 |
41,30 |
109,00 |
| Ergebnis je Aktie8 |
0,53 |
0,73 |
0,65 |
0,02 |
0,42 |
0,38 |
0,58 |
| Dividende8 |
0,22 |
0,29 |
0,00 |
0,00 |
0,00 |
0,15 |
0,35 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2023 - Kostenfrei herunterladen. 
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: KPMG
|
| INVESTOR-INFORMATIONEN |
| ©boersengefluester.de |
| Rhön-Klinikum |
| WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
| 704230 |
12,600 |
Halten |
843,73 |
| KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
| 21,00 |
28,42 |
0,73 |
21,54 |
| KBV |
KCV |
KUV |
EV/EBITDA |
| 0,67 |
7,74 |
0,58 |
7,38 |
| Dividende '22 in € |
Dividende '23 in € |
Div.-Rendite '23
in % |
Hauptversammlung |
| 0,15 |
0,00 |
0,00 |
05.06.2024 |
| Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
| 08.05.2024 |
08.08.2024 |
07.11.2024 |
28.03.2024 |
| Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
| 2,05% |
5,27% |
26,00% |
9,57% |
|
|
RHÖN-KLINIKUM Aktiengesellschaft DE0007042301